No profile data available.
Alpha Cognition Inc. (ACOG) is a healthcare company in the brain and nerve treatment drugs industry, based in Grapevine, United States, with about 71 full-time employees.
It reported revenue of $10.22 million for fiscal year 2025, and net income of -$20.67 million. United States was its largest region in fiscal year 2025, with 66% of revenue. Its market capitalization was $196.87 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Alpha Cognition reported $10.22 million in revenue for fiscal year 2025.
United States: 66% of revenue by region in fiscal year 2025, followed by China (34%).
$196.87 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include AC Immune SA (ACIU), Alector, Inc. (ALEC), Entrada Therapeutics, Inc. (TRDA), Inhibikase Therapeutics, Inc. (IKT).